PRKACB

Across TCGA pan-cancer cohorts, PRKACB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRKACB data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRKACB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRKACB expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where PRKACB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	1.000	0.666	.002	25	view →
LSCC	DFS	Quartile	II,III,IV	0.437	0.921	.005	19	view →
CCRCC	DFS	Tertile	IV	0.174	0.961	.024	12	view →
UCEC	DFS	Tertile	All	0.918	0.758	.046	2	view →
HNSC	DFS	Median	II,III,IV	0.897	0.976	.036	1	view →
LUAD	DFS	Quartile	All	1.000	0.670	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRKACB–PDAC (OS)

Open the PDAC breakdown →